Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The impact of rifaximin on the NHS hospital resource use associated with the management of patients with hepatic encephalopathy (HE): a retrospective observational study

Trial Profile

The impact of rifaximin on the NHS hospital resource use associated with the management of patients with hepatic encephalopathy (HE): a retrospective observational study

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 25 May 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rifaximin (Primary)
  • Indications Hepatic encephalopathy
  • Focus Therapeutic Use
  • Acronyms IMPRESS
  • Sponsors Norgine
  • Most Recent Events

    • 21 Apr 2017 According to a Norgine media release, data was presented at The International Liver Congress in April 2017.
    • 02 Nov 2016 Results assessing the impact of rifaximin-aplha on the costs associated with hospital admissions and attendances in patients with Hepatic-encephalopathy, presented at the 19th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
    • 31 Oct 2016 Results published in Norgine media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top